Background:
BMS-986488 is an investigational drug being studied for its safety, tolerability, and potential anti-cancer effects. It is being tested in combination with other cancer therapies.
Nivolumab (Opdivo®) is an immunotherapy that works by boosting the body’s immune system to recognize and attack cancer cells.
Since this drug is still in the clinical trial phase, it has the placeholder name BMS-986488 rather than a commercial trade name.
The Trial:
This study will investigate safety and effectiveness as a anti-cancer drug of BMS-986488, alone, or in combination with other drugs such as Adagrasib, Cetuximab, and Nivolumab in patients with advanced malignant tumors.
Kidney cancer participants will be sequentially assigned to one of the below treatment regimes:
- BMS-986488 alone
- BMS-986488 + Nivolumab
The trial is not “blind”, so both you and your doctor will know which therapy you are receiving.
Basic Eligibility:
- Clear cell renal cell carcinoma only (ccRCC)
- Cancer is locally advanced, metastatic, or cannot be removed by surgery
Additional eligibility criteria will apply. Please speak to your doctor.
Hospital / Cancer Centre | Principal Investigator | Location | Trial Status |
---|---|---|---|
Hospital / Cancer CentreBC Cancer | Principal InvestigatorDr. Christian Kollmannsberger | LocationVancouver, BC | Trial StatusRecruiting |
Hospital / Cancer CentreCentre intégré de cancérologie du CHU de Québec Université Laval | Principal InvestigatorDr. Antoine Morin Coulombe | LocationQuebec city, QC | Trial StatusRecruiting |
Hospital / Cancer CentreCentre Hospitalier de l'Université de Montréal (CRCHUM) | Principal InvestigatorNot Given | LocationMontreal, QC | Trial StatusNot Yet Recruiting |